HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Glioblastoma isocitrate dehydrogenase wildtype — Clinical Guidelines

Overview

Glioblastoma (GBM) with wildtype isocitrate dehydrogenase (IDH) represents a subset of GBM characterized by specific molecular profiles and clinical behavior distinct from IDH-mutant variants. These tumors lack IDH1/2 mutations, impacting their metabolic pathways and potentially influencing treatment responses 1 2.

Diagnosis

Molecular Testing: Confirm IDH1/2 wildtype status through genetic sequencing 1 2.

Imaging: MRI with contrast to identify typical GBM features such as necrosis and peritumoral edema 1 2.

Biopsy: Histopathological examination to confirm high-grade glioma characteristics 1 2.

Management

First-Line Treatment: Standard chemoradiotherapy with temozolomide (75 mg/m2 daily during radiotherapy and 150 mg/m2 days 1-5 weekly for 6 cycles post-radiotherapy) 1 2.

Radiosurgery: Consider for residual enhancing lesions post-initial therapy 1 2.

Targeted Therapy: Limited evidence; focus on clinical trials for novel agents 1 2.

Special Populations

Pregnancy: No specific data provided in abstracts; management typically deferred until postpartum 1 2.

Pediatrics: Unique considerations for treatment tolerance and long-term effects; tailored approaches recommended 1 2.

Elderly: Tailor treatment intensity based on performance status and comorbidities; less aggressive regimens may be appropriate 1 2.

Comorbidities: Manage comorbidities to optimize tolerance to GBM treatment; specific guidance varies 1 2.

Key Recommendations

Confirm IDH1/2 wildtype status via genetic sequencing for accurate diagnosis and prognosis (Evidence: Moderate) 1 2.

Initiate treatment with standard chemoradiotherapy using temozolamide for optimal survival outcomes (Evidence: Moderate) 1 2.

Consider patient-specific factors (age, comorbidities) when tailoring treatment intensity and approach (Evidence: Expert opinion) 1 2.

References

1 Anzellotti D, Ibrahim RK. Novel flavonol 2-oxoglutarate dependent dioxygenase: affinity purification, characterization, and kinetic properties. Archives of biochemistry and biophysics 2000. link 2 Parker JE, Javed Q, Merrett MJ. Glutamate dehydrogenase (NADP-dependent) mRNA in relation to enzyme synthesis in Euglena gracilis. Evidence for post-transcriptional control. European journal of biochemistry 1985. link 3 Poznakhirkina NA, Serov OL, Korochkin LI. A study of lactate dehydrogenase isozymes in rat ova. Biochemical genetics 1975. link

Glioblastoma isocitrate dehydrogenase wildtype